Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00316940
Recruitment Status : Completed
First Posted : April 21, 2006
Last Update Posted : September 20, 2013
Information provided by:
National Cancer Institute (NCI)